vs
Side-by-side financial comparison of ALNYLAM PHARMACEUTICALS, INC. (ALNY) and EPAM Systems (EPAM). Click either name above to swap in a different company.
EPAM Systems is the larger business by last-quarter revenue ($1.4B vs $1.2B, roughly 1.2× ALNYLAM PHARMACEUTICALS, INC.). ALNYLAM PHARMACEUTICALS, INC. runs the higher net margin — 17.6% vs 5.9%, a 11.8% gap on every dollar of revenue. On growth, ALNYLAM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (96.4% vs 7.6%). Over the past eight quarters, ALNYLAM PHARMACEUTICALS, INC.'s revenue compounded faster (33.0% CAGR vs 10.5%).
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
EPAM Systems, Inc. is an American company that specializes in software engineering services, digital platform engineering, and digital product design, operating out of Newtown, Pennsylvania. EPAM is a founding member of the MACH Alliance.
ALNY vs EPAM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.4B |
| Net Profit | $206.0M | $82.5M |
| Gross Margin | 82.2% | — |
| Operating Margin | 23.0% | 8.3% |
| Net Margin | 17.6% | 5.9% |
| Revenue YoY | 96.4% | 7.6% |
| Net Profit YoY | — | 12.3% |
| EPS (diluted) | $1.51 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.2B | $1.4B | ||
| Q4 25 | $1.1B | $1.4B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $773.7M | $1.4B | ||
| Q1 25 | $594.2M | $1.3B | ||
| Q4 24 | $593.2M | $1.2B | ||
| Q3 24 | $500.9M | $1.2B | ||
| Q2 24 | $659.8M | $1.1B |
| Q1 26 | $206.0M | $82.5M | ||
| Q4 25 | $186.4M | $109.4M | ||
| Q3 25 | $251.1M | $106.8M | ||
| Q2 25 | $-66.3M | $88.0M | ||
| Q1 25 | $-57.5M | $73.5M | ||
| Q4 24 | $-83.8M | $103.3M | ||
| Q3 24 | $-111.6M | $136.3M | ||
| Q2 24 | $-16.9M | $98.6M |
| Q1 26 | 82.2% | — | ||
| Q4 25 | 75.6% | 30.1% | ||
| Q3 25 | 84.2% | 29.5% | ||
| Q2 25 | 81.6% | 28.8% | ||
| Q1 25 | 88.2% | 26.9% | ||
| Q4 24 | 82.7% | 30.4% | ||
| Q3 24 | 83.6% | 34.6% | ||
| Q2 24 | 89.8% | 29.3% |
| Q1 26 | 23.0% | 8.3% | ||
| Q4 25 | 12.0% | 10.6% | ||
| Q3 25 | 29.5% | 10.4% | ||
| Q2 25 | -2.1% | 9.3% | ||
| Q1 25 | 3.0% | 7.6% | ||
| Q4 24 | -17.7% | 10.9% | ||
| Q3 24 | -15.4% | 15.2% | ||
| Q2 24 | 7.4% | 10.5% |
| Q1 26 | 17.6% | 5.9% | ||
| Q4 25 | 17.0% | 7.8% | ||
| Q3 25 | 20.1% | 7.7% | ||
| Q2 25 | -8.6% | 6.5% | ||
| Q1 25 | -9.7% | 5.6% | ||
| Q4 24 | -14.1% | 8.3% | ||
| Q3 24 | -22.3% | 11.7% | ||
| Q2 24 | -2.6% | 8.6% |
| Q1 26 | $1.51 | $1.52 | ||
| Q4 25 | $1.44 | $1.97 | ||
| Q3 25 | $1.84 | $1.91 | ||
| Q2 25 | $-0.51 | $1.56 | ||
| Q1 25 | $-0.44 | $1.28 | ||
| Q4 24 | $-0.66 | $1.80 | ||
| Q3 24 | $-0.87 | $2.37 | ||
| Q2 24 | $-0.13 | $1.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $1.0B |
| Total DebtLower is stronger | — | $165.0M |
| Stockholders' EquityBook value | $1.1B | $3.4B |
| Total Assets | $5.1B | $4.7B |
| Debt / EquityLower = less leverage | — | 0.05× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.7B | $1.0B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.1B | $1.0B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $966.4M | $1.3B | ||
| Q3 24 | $1.1B | $2.1B | ||
| Q2 24 | $968.5M | $1.8B |
| Q1 26 | — | $165.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.1B | $3.4B | ||
| Q4 25 | $789.2M | $3.7B | ||
| Q3 25 | $233.9M | $3.7B | ||
| Q2 25 | $250.6M | $3.7B | ||
| Q1 25 | $115.4M | $3.6B | ||
| Q4 24 | $67.1M | $3.6B | ||
| Q3 24 | $32.4M | $3.6B | ||
| Q2 24 | $-3.1M | $3.4B |
| Q1 26 | $5.1B | $4.7B | ||
| Q4 25 | $5.0B | $4.9B | ||
| Q3 25 | $4.9B | $4.8B | ||
| Q2 25 | $4.6B | $4.7B | ||
| Q1 25 | $4.2B | $4.7B | ||
| Q4 24 | $4.2B | $4.8B | ||
| Q3 24 | $4.2B | $4.5B | ||
| Q2 24 | $4.0B | $4.2B |
| Q1 26 | — | 0.05× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALNY
| AMVUTTRA | $889.9M | 76% |
| GIVLAARI | $74.4M | 6% |
| OXLUMO | $51.3M | 4% |
| Royalty revenue | $49.0M | 4% |
| Regeneron Pharmaceuticals | $46.3M | 4% |
| Roche | $35.6M | 3% |
| ONPATTRO | $20.5M | 2% |
EPAM
Segment breakdown not available.
